Congress Materials – CHEST 2024
2024 CHEST | Oct 6-9 | Boston, MA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Characteristics and outcomes of patients with pulmonary arterial hypertension and self-reported mental health comorbidities in the SPHERE (Selexipag: the users drug registry)
Vallerie McLaughlin, Harrison W. Farber, Kristin B. Highland, Nick H. Kim, Murali M. Chakinala, Kelly M. Chin, Michelle Han, Gurinderpal Doad, Paul Strachan, Michelle Cho, Tobore Tobore, Mohammad Rahman, and Anna R. Hemnes
Characteristics and outcomes of patients with pulmonary arterial hypertension transitioning to selexipag from another prostacyclin pathway agent in the SPHERE registry
Murali M. Chakinala, Vallerie McLaughlin, Harrison W. Farber, Kristin B. Highland, MD, Anna R. Hemnes, Kelly M. Chin, Michelle Han, Gurinderpal Doad, Paul Strachan, Michelle Cho, Tobore Tobore, Mohammad Rahman, and Nick H. Kim
Characteristics, treatment patterns, and outcomes of patients with pulmonary arterial hypertension by race: real-world data from the combined OPUS/ORPHEUS studies
McLaughlin VV, Channick R, Melendres-Groves L, Chin KM, MacDonald G, Martin N, Ong R, Sandros M, Kim NH, Gwen MacDonald
Characteristics, treatment patterns, and outcomes of pulmonary arterial hypertension patients by ethnicity: real-world data from the combined OPUS/ORPHEUS studies
Melendres-Groves Chin KM, Kim NH, McLaughlin VV, MacDonald G, Martin N, Ong R, Sandros M, Channick R, Gwen MacDonald
Expert consensus exploring the definition of a disease-modifying therapy, and the data requirements to establish a therapy as disease-modifying in pulmonary arterial hypertension
Vallerie McLaughlin, Robert Frantz, Anna Hemnes, Franck Rahaghi, Sandeep Sahay, Michelle Cho, Gurinderpal Doad, Jenny Lam, David Lopez, Daisy Bridge, Ashley Enstone, Richard Perry, Lisa Perret, Holly Smith, Medi Stone, Paul Strachan
Expert consensus on the definition of methamphetamine-associated pulmonary arterial hypertension (Meth-APAH) and associated treatment considerations
Roham Zamanian, Nick Kim, Peter Leary, Therese Sargent, John Kingrey, Ankita Adhia, David Lopez, Ashley Enstone, Richard Perry, Daisy Bridge, Medi Stone, Lisa Perrett, Holly Smith , Marinella Sandros
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.